Lidocaine (hydrochloride)

Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

Product Specifications

CAS Number

[73-78-9]

Product Name Alternative

Lignocaine hydrochloride

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; ERK; MEK; NF-κB; Sodium Channel

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Lidocaine-hydrochloride.html

Purity

99.90

Solubility

DMSO : ≥ 100 mg/mL|H2O : ≥ 100 mg/mL

Smiles

O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.[H]Cl

Molecular Formula

C14H23ClN2O

Molecular Weight

270.80

Precautions

H302, H315, H319, H335

References & Citations

[1]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582 (Pt 1) :11.|[2]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19 (1) :233.|[3]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113 (1) :31-6.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

ERK; MEK; NF-κB

Citation 01

Biomater Adv. 2025 Aug 15:178:214452.|Eur Spine J. 2022 Nov;31 (11) :2960-2971.|J Phys D Appl Phys. 2019 Aug; 52 (46) .|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Dig Dis Sci. 2021 Dec;66 (12) :4384-4397.|Drug Des Devel Ther. 2024 Apr 9:18:1103-1114.|Int Immunopharmacol. 2023 Feb:115:109706.|J Ethnopharmacol. 2025 Apr 14:347:119803.|J Neuroinflammation. 2017 Nov 2;14 (1) :211.|Mol Med Rep. 2022 May;25 (5) :150.|Nat Methods. 2021 Jul;18 (7) :788-798.|Neurogastroenterol Motil. 2023 Nov;35 (11) :e14677.|PLoS One. 2025 Nov 4;20 (11) :e0335932.|PLoS Pathog. 2023 Feb 3;19 (2) :e1011126.|Reprod Toxicol. 2025 May:134:108895.|Stem Cell Res Ther. 2021 Feb 4;12 (1) :107.|Transl Psychiatry. 2025 May 17;15 (1) :172.|University of Glasgow. School of Cancer Sciences.